Aa
new research
I am so happy to hear of any research for HCV that doesn't include interferon.
Thanks to mikesimon for letting me about this one.
(May 5, 2009 09:00 PM
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV). The new antibody effectively neutralized the virus in culture, and then prevented infection by the virus in a pre-clinical animal model of the disease.)
(August 6, 2009)
The University of Massachusetts Medical School's MassBiologics laboratory in Boston has begun the first phase of a clinical trial of a new Hepatitis C treatment.
The treatment is based on an antibody called MBL-HCV1. It will be given to 30 volunteers in escalating doses until the trial concludes later this year. A second phase will focus on liver transplant patients.
Hepatitis C attacks the liver and can lead to liver failure. The virus kills about 10,000 people annually and more than 3 million Americans are chronically infected with Hepatitis C.
The antibody developed by MassBiologics is designed to be used shortly before and after liver transplant surgery. Researchers also think it could be used in patients that are newly diagnosed with Hepatitis C.
MassBiologics is a nonprofit, licensed manufacturer of vaccines and other biologic products. The laboratory produces 30 percent of the United States' tetanus/diphtheria vaccine supply. It is run by UMass Medical School professor Donna Ambrosino.
Thanks to mikesimon for letting me about this one.
(May 5, 2009 09:00 PM
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV). The new antibody effectively neutralized the virus in culture, and then prevented infection by the virus in a pre-clinical animal model of the disease.)
(August 6, 2009)
The University of Massachusetts Medical School's MassBiologics laboratory in Boston has begun the first phase of a clinical trial of a new Hepatitis C treatment.
The treatment is based on an antibody called MBL-HCV1. It will be given to 30 volunteers in escalating doses until the trial concludes later this year. A second phase will focus on liver transplant patients.
Hepatitis C attacks the liver and can lead to liver failure. The virus kills about 10,000 people annually and more than 3 million Americans are chronically infected with Hepatitis C.
The antibody developed by MassBiologics is designed to be used shortly before and after liver transplant surgery. Researchers also think it could be used in patients that are newly diagnosed with Hepatitis C.
MassBiologics is a nonprofit, licensed manufacturer of vaccines and other biologic products. The laboratory produces 30 percent of the United States' tetanus/diphtheria vaccine supply. It is run by UMass Medical School professor Donna Ambrosino.
Boy wouldn't that be nice if that one pans out. Most of my problems with sx were due to interferon.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
